- Home
- AKBA vs IMMP Comparison
AKBA vs IMMP Comparison
Compare AKBA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- IMMP
- Stock Information
- Founded
- AKBA 2007
- IMMP 1987
- Country
- AKBA United States
- IMMP Australia
- Employees
- AKBA N/A
- IMMP N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- AKBA Health Care
- IMMP Health Care
- Exchange
- AKBA Nasdaq
- IMMP Nasdaq
- Market Cap
- AKBA 336.2M
- IMMP 304.0M
- IPO Year
- AKBA 2014
- IMMP N/A
- Fundamental
- Price
- AKBA $1.83
- IMMP $2.03
- Analyst Decision
- AKBA Strong Buy
- IMMP Buy
- Analyst Count
- AKBA 1
- IMMP 2
- Target Price
- AKBA $7.50
- IMMP $8.50
- AVG Volume (30 Days)
- AKBA 2.4M
- IMMP 159.0K
- Earning Date
- AKBA 11-07-2024
- IMMP 01-03-2025
- Dividend Yield
- AKBA N/A
- IMMP N/A
- EPS Growth
- AKBA N/A
- IMMP N/A
- EPS
- AKBA N/A
- IMMP N/A
- Revenue
- AKBA $169,879,000.00
- IMMP $2,563,302.00
- Revenue This Year
- AKBA N/A
- IMMP N/A
- Revenue Next Year
- AKBA $30.85
- IMMP $10.84
- P/E Ratio
- AKBA N/A
- IMMP N/A
- Revenue Growth
- AKBA N/A
- IMMP 9.59
- 52 Week Low
- AKBA $0.80
- IMMP $1.66
- 52 Week High
- AKBA $2.48
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- AKBA 46.55
- IMMP 47.96
- Support Level
- AKBA $1.74
- IMMP $2.00
- Resistance Level
- AKBA $1.90
- IMMP $2.24
- Average True Range (ATR)
- AKBA 0.09
- IMMP 0.13
- MACD
- AKBA -0.03
- IMMP -0.01
- Stochastic Oscillator
- AKBA 20.93
- IMMP 25.00
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.